DK1049712T3 - Hybrid-tetanus-toxoid-proteiner der retrogradt og transsynaptisk migrerer ind i CNS - Google Patents

Hybrid-tetanus-toxoid-proteiner der retrogradt og transsynaptisk migrerer ind i CNS

Info

Publication number
DK1049712T3
DK1049712T3 DK98945222T DK98945222T DK1049712T3 DK 1049712 T3 DK1049712 T3 DK 1049712T3 DK 98945222 T DK98945222 T DK 98945222T DK 98945222 T DK98945222 T DK 98945222T DK 1049712 T3 DK1049712 T3 DK 1049712T3
Authority
DK
Denmark
Prior art keywords
ttc
retrograde
hybrid
transsynaptically
cns
Prior art date
Application number
DK98945222T
Other languages
English (en)
Inventor
Philippe Brulet
Laurent Coen
Pinzolas Rosario Osta
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Application granted granted Critical
Publication of DK1049712T3 publication Critical patent/DK1049712T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK98945222T 1997-08-14 1998-08-12 Hybrid-tetanus-toxoid-proteiner der retrogradt og transsynaptisk migrerer ind i CNS DK1049712T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5561597P 1997-08-14 1997-08-14
US6523697P 1997-11-13 1997-11-13
PCT/EP1998/005113 WO1999009057A2 (en) 1997-08-14 1998-08-12 Hybrid tetanus toxoid proteins that migrate retrogradely and transynaptically into the cns

Publications (1)

Publication Number Publication Date
DK1049712T3 true DK1049712T3 (da) 2007-05-29

Family

ID=26734425

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98945222T DK1049712T3 (da) 1997-08-14 1998-08-12 Hybrid-tetanus-toxoid-proteiner der retrogradt og transsynaptisk migrerer ind i CNS

Country Status (9)

Country Link
US (4) US7435792B2 (da)
EP (2) EP1049712B1 (da)
AT (1) ATE352558T1 (da)
CY (1) CY1106504T1 (da)
DE (1) DE69836982T2 (da)
DK (1) DK1049712T3 (da)
ES (1) ES2281135T3 (da)
PT (1) PT1049712E (da)
WO (1) WO1999009057A2 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087171A (en) * 1993-12-17 2000-07-11 Spinal Cord Society Method for inducing DNA synthesis in neurons
US7923015B2 (en) 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
DK1049712T3 (da) * 1997-08-14 2007-05-29 Pasteur Institut Hybrid-tetanus-toxoid-proteiner der retrogradt og transsynaptisk migrerer ind i CNS
US7368532B2 (en) 1999-12-02 2008-05-06 Syntaxin Limited Constructs for delivery of therapeutic agents to neuronal cells
DE60008915T2 (de) * 1999-12-02 2005-01-20 Health Protection Agency, Salisbury Konstrukte zur verabreichung von therapeutischen wirkstoffen an die neuronzellen
AU2003268484A1 (en) * 2002-09-06 2004-03-29 The General Hospital Corporation Delivery of therapeutics to the brain and spinal cord
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US20080233049A1 (en) * 2004-06-23 2008-09-25 Ian Andrew Ferguson Agents And Methods For Early Diagnosis And Monitoring Of Alzheimer's Disease And Other Neurological Disorders
DK1976877T4 (da) 2005-11-30 2017-01-16 Abbvie Inc Monoklonale antistoffer mod amyloid-beta-protein og anvendelser heraf
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
US20080044348A1 (en) * 2006-06-30 2008-02-21 Gelovani Juri G Tetanus toxin fragment C based imaging agents and methods, and confocal microscopy dataset processes
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
ES2332628B1 (es) * 2007-10-05 2011-01-24 Universidad De Zaragoza Uso de la secuencia codificante del dominio carboxilo terminal de la cadena pesada de la toxina tetanica como medicamento.
US8173768B2 (en) * 2009-07-13 2012-05-08 Centre National De La Recherche Scientifique Peptides having antimicrobial and neurotrophic activity and uses thereof
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
WO2011143557A2 (en) 2010-05-14 2011-11-17 The Children's Hospital Of Philadelphia Humanized ttc and methods of use thereof
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
WO2016001762A1 (en) 2014-07-02 2016-01-07 Spherium Biomed S.L. Methods of increasing muscle mass using non-toxic tetanus toxin c fragment (ttc)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470773B1 (da) * 1979-11-28 1983-01-28 Pasteur Institut
CA1178949A (en) 1979-11-28 1984-12-04 Bernard Bizzini Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its applications
FR2498192A2 (fr) 1981-01-22 1982-07-23 Pasteur Institut Nouveau compose polypeptidique thiole provenant d'un fragment de la toxine tetanique, son procede d'obtention et ses applications
US4594336A (en) 1982-09-28 1986-06-10 Institut Pasteur Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application
US5004683A (en) * 1986-07-31 1991-04-02 The Research Foundation Of State University Of New York Means for detecting and analyzing neuroanatomy
US5728383A (en) 1987-10-05 1998-03-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatment of tumors of the central nervous system with immunotoxins
US5650148A (en) 1988-12-15 1997-07-22 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GB8914122D0 (en) * 1989-06-20 1989-08-09 Wellcome Found Polypeptide expression
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5766948A (en) * 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
CA2168459C (en) * 1993-07-30 2002-10-01 Mohammed Anjam Khan Fusion proteins containing the c-terminal of tetanus toxin linked to a heterologous protein
US6551618B2 (en) * 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
US5728399A (en) 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
US5716614A (en) * 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5580839A (en) * 1994-09-30 1996-12-03 University Of Kentucky Research Foundation Binary ferrihydrite catalysts
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US5780024A (en) 1995-06-23 1998-07-14 The General Hospital Corp. Superoxide dismutase/tetanus toxin fragment C hybrid protein
WO1997040847A1 (en) 1996-04-26 1997-11-06 University Of Ottawa Therapeutic and drug screening methods for the treatment and prevention of neuronal disease
US5738383A (en) * 1996-11-20 1998-04-14 Kobel, Inc. Label assembly with patterned adhesive bands
US7923015B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur Methods for direct visualization of active synapses
US20100081197A1 (en) * 1997-08-14 2010-04-01 Sylvie Roux In vivo modulation of neuronal transport
DK1049712T3 (da) * 1997-08-14 2007-05-29 Pasteur Institut Hybrid-tetanus-toxoid-proteiner der retrogradt og transsynaptisk migrerer ind i CNS
US7923216B2 (en) * 1997-08-14 2011-04-12 Institut Pasteur In vivo modulation of neuronal transport
US20030083299A1 (en) * 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
US20030031702A1 (en) * 2001-07-27 2003-02-13 Mazur Leonard L. Safer teratogenic pharmaceuticals
US20070092449A1 (en) * 2005-04-05 2007-04-26 Rafael Vazquez-Martinez Methods for direct visualization of active synapses

Also Published As

Publication number Publication date
ES2281135T3 (es) 2007-09-16
EP1049712B1 (en) 2007-01-24
DE69836982T2 (de) 2007-10-31
US7435792B2 (en) 2008-10-14
PT1049712E (pt) 2007-04-30
EP1681300A1 (en) 2006-07-19
ATE352558T1 (de) 2007-02-15
US20090226468A1 (en) 2009-09-10
CY1106504T1 (el) 2012-01-25
DE69836982D1 (de) 2007-03-15
EP1049712A2 (en) 2000-11-08
US20100239534A1 (en) 2010-09-23
WO1999009057A2 (en) 1999-02-25
US20030004121A1 (en) 2003-01-02
US20110002914A1 (en) 2011-01-06
WO1999009057A3 (en) 1999-07-08

Similar Documents

Publication Publication Date Title
DK1049712T3 (da) Hybrid-tetanus-toxoid-proteiner der retrogradt og transsynaptisk migrerer ind i CNS
NZ504548A (en) Polypeptides and nucleic acids encoding human chordin
NZ295673A (en) Nucleic acid transfer system using recombinant multi-domain proteins each domain having a different function
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
DE68927161D1 (de) Zellulosebindende fusionsproteine
ATE331438T1 (de) Rezeptorspezifischer transepithelealer transport von immunogenen
DK1265914T3 (da) WNT-1-relaterede polypeptider og nukleinsyrer, der koder for samme
DE69131929D1 (de) Methoden zur trans-destabilisierung von spezifischen proteinen in vivo
WO1999025878A3 (en) Methods for modulating and identifying cellular senescence
DE69333985D1 (de) Allergene proteine und peptide von hundhautanhangsgebilden und ihre verwendung
WO1996009386A3 (en) Allelic variation of the serotonin 5ht2c receptor
FI880017A (fi) Menetelmä haiman erittämän trypsiini-inhibiittorivarianttien valmistamiseksi ja menetelmässä käytettävä DNA, vektori ja isäntäsolu
DE60008915D1 (de) Konstrukte zur verabreichung von therapeutischen wirkstoffen an die neuronzellen
BR0205083A (pt) Polipeptìdeo isolado, composição farmacêutica, proteìna de fusão, polinucleotìdeo isolado, vetor de expressão, célula hospedeira recombinante e métodos de produzir um polipeptìdeo, de detectar a presença da expressão de gene em uma amostra biológica, de expandir células monocìticas ou progenitores de células de monócitos e de estimular uma resposta imune em um mamìfero exposto a um antìgeno ou patógeno
NZ527971A (en) Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon
DE69532122D1 (de) Erhöhte produktion von beta-galaktosidase in aspergillus oryzae
DE60036555D1 (de) Polypeptidfragmente mit einem c-terminalen teil von katalase aus helicobacter
DE69121489D1 (de) In vitro-Behandlung von Fusionsproteinen
WO2001030968A3 (en) Glutamate transporter associated proteins and methods of use thereof
ATE103341T1 (de) Antikoerper gegen hochkonservierte aminosaeuresequenzen von immunogenen substanzen, verfahren zur herstellung dieser antikoerper, sowie deren verwendung in immunoassays.
ES2181444T3 (es) Composicion para la induccion de una respuesta inmunologica especifica de un tumor, metodo para la produccion y utilizacion de dicha composicion en el tratamiento de neoplasias.
GUNDLACH Conformational Changes in Chymotrypsin Detected with Antibodies, II. Antibody-interactions with chemically modified and denatured chymotrypsins
Hare Characterization and regulation of serine exoproteases and collagenase in vibrio alginolyticus
Müller et al. The 3rd German-Japanese Joint Workshop. Cell Death in the CNS: Molecules and Programs
DE69303840D1 (de) Neue Polypeptide, deren kodierende DNS